GEN-MKT-18-7897-A
Mar 28, 2018 | Blogs, Life Science Research, Lipidomics | 0 comments
Lipidomics research has progressed rapidly in the last decade. Twenty years ago, the determination of the lipid composition of a biological sample required slow and extensive multi-dimensional chromatographic separation and chemical derivatization strategies. Today, in-depth analysis can be performed quickly using high throughput analysis by mass spectrometry.
Advances in mass spectrometry have enabled in-depth lipidomic analyses with unparalleled qualitative and quantitative sensitivity. However, unambiguous identification and quantitation of lipid molecular species in total lipid extracts has proven to be difficult, primarily due to isobaric overlapping isobaric and isomeric species. There are greater than 100,000 lipid molecular species present in a typical biological lipid extract that occupy a narrow mass range (~400-1100 amu), making such overlap a significant problem.
SelexION Technology represents the next technological advance and is uniquely suited for lipidomic research. Using Differential Mobility Separation (DMS) as an upfront orthogonal separation enables the resolution of complex lipid mixtures, effectively addressing the problem of isobaric interferences among different lipid classes and sub-classes.
Key Features of SelexION Technology for Lipid Analysis
SelexION Technology is a planar differential mobility device that separates analytes based on differences in their chemical properties, prior to entering the instrument orifice, thus providing an orthogonal level of selectivity.
Read our technical paper to see how we effectively resolves multiple lipid classes from complex mixtures prior to analysis by mass spectrometry. By removing isobaric and isomeric interferences, lipid analysis by QTRAP systems using SelexION Technology enables more confident identification of lipid molecular species and provides for more accurate relative quantitation by MS/MS.
In monoclonal antibody (mAb) development, assessment of purity and integrity of the protein in question is critical. CE‑SDS is the gold standard assay and is routinely run from analytical development through QC and lot release. It’s trusted because it consistently delivers quantitative, size‑based insight into purity and fragmentation, and it fits naturally into regulated environments.
In drug discovery and development, Metabolite Identification (Met ID) plays a critical role in understanding biotransformation pathways, ensuring safety, and meeting regulatory requirements. Advanced mass spectrometry techniques have revolutionized this process, particularly through electron-based fragmentation methods such as Electron Activated Dissociation (EAD) and Electron Transfer Dissociation (ETD). While both techniques leverage electron interactions to generate informative fragment ions, they differ significantly in mechanism, performance, and suitability for Met ID workflows.
In analytical laboratories, performance is not optional. Whether supporting regulated pharmaceutical workflows, high-throughput CRO operations, clinical reporting, or food and environmental testing, your mass spectrometry and capillary electrophoresis systems are critical to productivity, compliance, and scientific confidence.
Posted by
You must be logged in to post a comment.
Share this post with your network